{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:32:56Z","timestamp":1788582776904,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R34HL121402"],"award-info":[{"award-number":["1R34HL121402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R34HL121402"],"award-info":[{"award-number":["1R34HL121402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-\u03b2 regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in myocardial infarction. However, the effect of IL-1 blockade with anakinra on leukocyte count in patients with STEMI is unknown. We reviewed the white blood cell (WBC) and differential count of 99 patients enrolled in a clinical trial of anakinra (n\u2009=\u200964) versus placebo (n\u2009=\u200935) for 14\u00a0days after STEMI. A complete blood cell count with differential count were obtained at admission, and after 72\u00a0h, 14\u00a0days and 3\u00a0months. After 72\u00a0h from treatment, anakinra compared to placebo led to a statistically significant greater percent reduction in total WBC count (\u2212\u200935% [\u2212\u200948 to \u2212\u200924] vs. \u2212\u200921% [\u2212\u200934 to \u2212\u200910], <jats:italic>P<\/jats:italic>\u2009=\u20090.008), absolute neutrophil count (\u2212\u200948% [\u2212\u200960 to \u2212\u200922] vs. \u2212\u200927% [\u2212\u200946 to \u2212\u20095], <jats:italic>P<\/jats:italic>\u2009=\u20090.004) and to an increase in absolute eosinophil count (+\u200950% [0 to\u2009+\u2009100] vs. 0% [\u2212\u200950 to\u2009+\u200962], <jats:italic>P<\/jats:italic>\u2009=\u20090.022). These changes persisted while on treatment at 14\u00a0days and were no longer apparent at 3\u00a0months after treatment discontinuation. We found that in patients with STEMI IL-1 blockade with anakinra accelerates resolution of leukocytosis and neutrophilia. This modulation may represent one of the mechanisms by which IL-1 blockade improves clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41598-022-05374-w","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:03:57Z","timestamp":1643022237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction"],"prefix":"10.1038","volume":"12","author":[{"given":"Marco Giuseppe","family":"Del Buono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Damonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory R.","family":"Trankle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kadariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Turlington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshanak","family":"Markley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Canada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe G.","family":"Biondi\u2010Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kontos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Van Tassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"29","key":"5374_CR1","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/eurheartj\/eht529","volume":"35","author":"SD Kristensen","year":"2014","unstructured":"Kristensen, S. D. et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010\/2011: Current status in 37 ESC countries published correction appears in Eur Heart J. 2014 Oct 7;35(38):2697]. Eur. Heart J. 35(29), 1957\u20131970. https:\/\/doi.org\/10.1093\/eurheartj\/eht529 (2014).","journal-title":"Eur. Heart J."},{"issue":"4","key":"5374_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2018","unstructured":"Toldo, S. & Abbate, A. The NLRP3 inflammasome in acute myocardial infarction. Nat. Rev. Cardiol. 15(4), 203\u2013214. https:\/\/doi.org\/10.1038\/nrcardio.2017.161 (2018).","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"5374_CR3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.amjcard.2003.11.013","volume":"93","author":"AJ Kirtane","year":"2004","unstructured":"Kirtane, A. J., Bui, A., Murphy, S. A., Barron, H. V. & Gibson, C. M. Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. Am. J. Cardiol. 93(5), 532\u2013536. https:\/\/doi.org\/10.1016\/j.amjcard.2003.11.013 (2004).","journal-title":"Am. J. Cardiol."},{"issue":"1 Pt 1","key":"5374_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/s0002-8703(00)90314-4","volume":"139","author":"L Kyne","year":"2000","unstructured":"Kyne, L. et al. Neutrophilia and congestive heart failure after acute myocardial infarction. Am. Heart J. 139(1 Pt 1), 94\u2013100. https:\/\/doi.org\/10.1016\/s0002-8703(00)90314-4 (2000).","journal-title":"Am. Heart J."},{"issue":"8","key":"5374_CR5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/eurheartj\/ehn112","volume":"29","author":"M O'Donoghue","year":"2008","unstructured":"O\u2019Donoghue, M. et al. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur. Heart J. 29(8), 984\u2013991. https:\/\/doi.org\/10.1093\/eurheartj\/ehn112 (2008).","journal-title":"Eur. Heart J."},{"issue":"4","key":"5374_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/2048872615568965","volume":"5","author":"IM Seropian","year":"2016","unstructured":"Seropian, I. M., Sonnino, C., Van Tassell, B. W., Biasucci, L. M. & Abbate, A. Inflammatory markers in ST-elevation acute myocardial infarction. Eur. Heart J. Acute Cardiovasc. Care 5(4), 382\u2013395. https:\/\/doi.org\/10.1177\/2048872615568965 (2016).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"12","key":"5374_CR7","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1084\/jem.20070885","volume":"204","author":"M Nahrendorf","year":"2007","unstructured":"Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204(12), 3037\u20133047. https:\/\/doi.org\/10.1084\/jem.20070885 (2007).","journal-title":"J. Exp. Med."},{"issue":"3","key":"5374_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/eurheartj\/ehw002","volume":"38","author":"M Horckmans","year":"2017","unstructured":"Horckmans, M. et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur. Heart J. 38(3), 187\u2013197. https:\/\/doi.org\/10.1093\/eurheartj\/ehw002 (2017).","journal-title":"Eur. Heart J."},{"issue":"13","key":"5374_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1161\/CIRCULATIONAHA.119.043833","volume":"141","author":"G Sreejit","year":"2020","unstructured":"Sreejit, G. et al. Neutrophil-derived S100A8\/A9 amplify granulopoiesis after myocardial infarction. Circulation 141(13), 1080\u20131094. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.043833 (2020).","journal-title":"Circulation"},{"issue":"5","key":"5374_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis, N. G. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 11(5), 255\u2013265. https:\/\/doi.org\/10.1038\/nrcardio.2014.28 (2014).","journal-title":"Nat. Rev. Cardiol."},{"issue":"13","key":"5374_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1089\/ars.2014.5989","volume":"22","author":"S Toldo","year":"2015","unstructured":"Toldo, S. et al. The inflammasome in myocardial injury and cardiac remodeling. Antioxid. Redox Signal. 22(13), 1146\u20131161. https:\/\/doi.org\/10.1089\/ars.2014.5989 (2015).","journal-title":"Antioxid. Redox Signal."},{"key":"5374_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijcard.2016.02.043","volume":"209","author":"S Toldo","year":"2016","unstructured":"Toldo, S. et al. Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse. Int. J. Cardiol. 209, 215\u2013220. https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.043 (2016).","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"5374_CR13","doi-asserted-by":"publisher","first-page":"H1553","DOI":"10.1152\/ajpheart.00158.2018","volume":"315","author":"S Toldo","year":"2018","unstructured":"Toldo, S., Mauro, A. G., Cutter, Z. & Abbate, A. Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 315(6), H1553\u2013H1568. https:\/\/doi.org\/10.1152\/ajpheart.00158.2018 (2018).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"20","key":"5374_CR14","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1161\/CIRCULATIONAHA.115.016160","volume":"132","author":"HB Sager","year":"2015","unstructured":"Sager, H. B. et al. Targeting interleukin-1\u03b2 reduces leukocyte production after acute myocardial infarction. Circulation 132(20), 1880\u20131890. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016160 (2015).","journal-title":"Circulation"},{"issue":"10","key":"5374_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","volume":"105","author":"A Abbate","year":"2010","unstructured":"Abbate, A. et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia commonwealth University anakinra remodeling trial [VCU-ART] pilot study). Am. J. Cardiol. 105(10), 1371-1377.e1. https:\/\/doi.org\/10.1016\/j.amjcard.2009.12.059 (2010).","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"5374_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2119\/molmed.2014.00121","volume":"20","author":"C Sonnino","year":"2014","unstructured":"Sonnino, C. et al. Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra. Mol. Med. 20(1), 486\u2013489. https:\/\/doi.org\/10.2119\/molmed.2014.00121 (2014).","journal-title":"Mol. Med."},{"issue":"5","key":"5374_CR17","doi-asserted-by":"publisher","first-page":"e014941","DOI":"10.1161\/JAHA.119.014941","volume":"9","author":"A Abbate","year":"2020","unstructured":"Abbate, A. et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J. Am. Heart Assoc. 9(5), e014941. https:\/\/doi.org\/10.1161\/JAHA.119.014941 (2020).","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"5374_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/clc.22988","volume":"41","author":"BW Van Tassell","year":"2018","unstructured":"Van Tassell, B. W. et al. Rationale and design of the Virginia commonwealth university-anakinra remodeling trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study. Clin. Cardiol. 41(8), 1004\u20131008. https:\/\/doi.org\/10.1002\/clc.22988 (2018).","journal-title":"Clin. Cardiol."},{"issue":"3","key":"5374_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.amjcard.2008.09.085","volume":"103","author":"S Chia","year":"2009","unstructured":"Chia, S. et al. Association of leukocyte and neutrophil counts with infarct size, left ventricular function and outcomes after percutaneous coronary intervention for ST-elevation myocardial infarction. Am. J. Cardiol. 103(3), 333\u2013337. https:\/\/doi.org\/10.1016\/j.amjcard.2008.09.085 (2009).","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"5374_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027923","volume":"6","author":"A Abbate","year":"2011","unstructured":"Abbate, A. et al. Alterations in the interleukin-1\/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS ONE 6(11), e27923. https:\/\/doi.org\/10.1371\/journal.pone.0027923 (2011).","journal-title":"PLoS ONE"},{"issue":"6","key":"5374_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.amjcard.2007.11.004","volume":"101","author":"J N\u00fa\u00f1ez","year":"2008","unstructured":"N\u00fa\u00f1ez, J. et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am. J. Cardiol. 101(6), 747\u2013752. https:\/\/doi.org\/10.1016\/j.amjcard.2007.11.004 (2008).","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"5374_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0192-0561(86)90070-6","volume":"8","author":"RJ Smith","year":"1986","unstructured":"Smith, R. J., Bowman, B. J. & Speziale, S. C. Interleukin-1 stimulates granule exocytosis from human neutrophils. Int. J. Immunopharmacol. 8(1), 33\u201340. https:\/\/doi.org\/10.1016\/0192-0561(86)90070-6 (1986).","journal-title":"Int. J. Immunopharmacol."},{"issue":"7","key":"5374_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00011-013-0625-0","volume":"62","author":"BW Van Tassell","year":"2013","unstructured":"Van Tassell, B. W., Seropian, I. M., Toldo, S., Mezzaroma, E. & Abbate, A. Interleukin-1\u03b2 induces a reversible cardiomyopathy in the mouse. Inflamm. Res. 62(7), 637\u2013640. https:\/\/doi.org\/10.1007\/s00011-013-0625-0 (2013).","journal-title":"Inflamm. Res."},{"issue":"10","key":"5374_CR24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","volume":"111","author":"A Abbate","year":"2013","unstructured":"Abbate, A. et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia commonwealth university-anakinra remodeling trial (2) (VCU-ART2) pilot study]. Am. J. Cardiol. 111(10), 1394\u20131400. https:\/\/doi.org\/10.1016\/j.amjcard.2013.01.287 (2013).","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"5374_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","volume":"115","author":"A Abbate","year":"2015","unstructured":"Abbate, A. et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am. J. Cardiol. 115(3), 288\u2013292. https:\/\/doi.org\/10.1016\/j.amjcard.2014.11.003 (2015).","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"5374_CR26","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","volume":"139","author":"BM Everett","year":"2019","unstructured":"Everett, B. M. et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation 139(10), 1289\u20131299. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038010 (2019).","journal-title":"Circulation"},{"key":"5374_CR27","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf"},{"issue":"1","key":"5374_CR28","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1038\/s41467-020-19297-5","volume":"11","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Eosinophils improve cardiac function after myocardial infarction. Nat Commun. 11(1), 6396. https:\/\/doi.org\/10.1038\/s41467-020-19297-5 (2020).","journal-title":"Nat Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05374-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:07:45Z","timestamp":1669324065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05374-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5374"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05374-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"7 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Abbate and Van Tassell have served as consultants to Swedish Orphan Biovitrum LLC in the past. The remaining authors have no disclosures to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1254"}}